A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB Subtype DLBCL (ACE-LY-312)
Status:
Recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety
of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP) vs placebo plus R-CHOP in subjects ≤65 years of age with previously untreated
non-germinal center diffuse large B-cell lymphoma.